Adrenoleukodystrophy (ALD) Market Insights, Epidemiology and Market Forecast - 2027

  • ID: 4520738
  • Drug Pipelines
  • 136 pages
  • DelveInsight
1 of 3
This report titled ‘Adrenoleukodystrophy (ALD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Adrenoleukodystrophy (ALD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Adrenoleukodystrophy from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Adrenoleukodystrophy Disease Understanding and Treatment Algorithm:

The Adrenoleukodystrophy market report gives the thorough understanding of ALD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for ALD in the US, Europe, and Japan.

Adrenoleukodystrophy Epidemiology:

The Adrenoleukodystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, diagnosed prevalence of ALD by clinical manifestations (cerebral ALD, Adrenomyleoneuropathy and Addison’s disease), diagnosed prevalence of CALD by segmentation (childhood, adolescent, adult ALD)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, total prevalent population of Adrenoleukodystrophy in 7 major markets are found to be about 26,866 in 2016.

Adrenoleukodystrophy Drug Chapters:

This segment of the Adrenoleukodystrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There is no approved therapy for the treatment of ALD in the market. The current therapeutic market is being ruled solely by transplantation [for severe cases of cerebral Adrenoleukodystrophy (CALD)] and steroids [in case of Adrenal insufficiency] in absence of any approved pharmacological therapy for the treatment of ALD in the United States. Detailed chapter for upcoming therapies Lenti-D (Gene therapy; Bluebird Bio), MIN-102 (Minoryx Therapeutics), OP-101 (Orpheris, Inc.), MD1003 (MedDay Pharma) and NV1205 (Sobetirome; NeuroVia, Inc) have been covered in the report.

Adrenoleukodystrophy Market Outlook:

The Adrenoleukodystrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Adrenoleukodystrophy in 7MM was found to be USD 135.9 million in 2016, and is expected to increase from 2016-2027.

Adrenoleukodystrophy Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adrenoleukodystrophy Report Insights:
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Adrenoleukodystrophy Report Key Strengths:
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Adrenoleukodystrophy Report Assessment:
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits:
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Adrenoleukodystrophy market
  • Organize sales and marketing efforts by identifying the best opportunities for Adrenoleukodystrophy market
  • To understand the future market competition in the Adrenoleukodystrophy market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. Adrenoleukodystrophy Market Overview at a Glance
2.1. Market Share (%) Distribution of Adrenoleukodystrophy in 2016
2.2. Market Share (%) Distribution of Adrenoleukodystrophy in 2027

3. Disease Background and Overview: Adrenoleukodystrophy (ALD)
3.1. Introduction
3.2. Clinical aspects of ALD
3.3. Disease Causes
3.4. Inheritance pattern of ALD
3.5. ALD-Symptoms
3.6. Pathogenesis
3.7. ALD Diagnosis
3.8. X-ALD Newborn Screening
3.9. Tools for evaluating Cerebral X-ALD

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Disease Definition
4.3. Population and Forecast Parameters

5. 7MM Prevalent Population of Adrenoleukodystophy (ALD)

6. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD)
6.1. United States
6.1.1. Prevalent Population of Adrenoleukodystrophy in United States
6.1.2. Diagnosed Prevalence of ALD by Clinical Manifestation in United States
6.1.3. Diagnosed Prevalence of CALD by Segmentation in United States
6.2. Germany
6.2.1. Prevalent Population of Adrenoleukodystrophy in Germany
6.2.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany
6.2.3. Diagnosed Prevalence of CALD by Segmentation in Germany
6.3. France
6.3.1. Prevalent Population of Adrenoleukodystrophy in France
6.3.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the France
6.3.3. Diagnosed Prevalence of CALD by Segmentation in France
6.4. Italy
6.4.1. Prevalent Population of Adrenoleukodystrophy in Italy
6.4.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy
6.4.3. Diagnosed Prevalence of CALD by Segmentation in Italy
6.5. Spain
6.5.1. Prevalent Population of Adrenoleukodystrophy in Spain
6.5.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain
6.5.3. Diagnosed Prevalence of CALD by Segmentation in Spain
6.6. United Kingdom
6.6.1. Prevalent Population of Adrenoleukodystrophy in United Kingdom
6.6.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the United Kingdom
6.6.3. Diagnosed Prevalence of CALD by Segmentation in United Kingdom
6.7. Japan
6.7.1. Prevalent Population of Adrenoleukodystrophy in Japan
6.7.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan
6.7.3. Diagnosed Prevalence of CALD by Segmentation in Japan

7. Current Treatment and Medical Practices
7.1. Subtype -Specific Treatment
7.2. Treatment Guidelines
7.3. Recommendations for Treatment of X-linked ALD in United States
7.4. Adrenoleukodystrophy treatment: European Leukodystrophies Association
7.5. Diagnostic and follow-up system for Adrenoleukodystrophy in Japan

8. Unmet Needs

9. Emerging Therapies
9.1. Key Cross Competition

10. Phase II/III Drugs
10.1. Lenti D: Bluebird Bio
10.1.1. Drug Description
10.1.2. Product Profile
10.1.3. Regulatory Milestones
10.1.4. Other Development Activities
10.1.5. Clinical Development
10.1.6. Clinical Trials Information
10.1.7. Safety and Efficacy
10.1.8. Advantages and Disadvantages
10.2. MIN-102: Minoryx Therapeutics, S.L.
10.2.1. Drug Description
10.2.2. Product Profile
10.2.3. Regulatory Milestones
10.2.4. Other Development Activities
10.2.5. Clinical Development
10.2.6. Clinical Trials Information
10.2.7. Safety and Efficacy
10.2.8. Advantages and Disadvantages
10.3. MD1003: MedDay Pharmaceuticals
10.3.1. Drug Description
10.3.2. Product Profile
10.3.3. Other Development Activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and Efficacy
10.3.7. Advantages and Disadvantages

11. Phase I/II Drugs
11.1. NV1205: NeuroVia, Inc.
11.1.1. Drug Description
11.1.2. Product Profile
11.1.3. Other Development Activities
11.1.4. Clinical Development
11.1.5. Clinical Trials Information
11.1.6. Safety and Efficacy
11.1.7. Advantages and Disadvantages
11.2. OP-101: Orpheris Inc.
11.3. Drug Description
11.4. Product Profile
11.5. Regulatory Milestones
11.6. Other Development Activities
11.7. Clinical Development

12. Adrenoleukodystrophy (ALD): Market Analysis
12.1. Key Findings
12.2. Assumptions and Forecasting Parameters
12.3. Key Events and Impacts

13. Adrenoleukodystrophy (ALD): Total Market Size in 7MM
13.1. Total Market Size of ALD in 7MM
13.2. Market size of ALD by Segmentation in 7MM
13.3. Therapy-based Market Size of ALD in 7MM
13.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in 7MM
13.5. Market size of CALD by Segmentation in 7MM
13.6. Therapy-based Market size of CALD in 7MM

14. Market Size of Adrenoleukodystrophy (ALD) by Country
14.1. United States Market Analysis
14.1.1. Market Size of ALD in the U.S.
14.1.2. Market size of ALD by Segmentation in the U.S.
14.1.3. Therapy-based Market Size of ALD in the U.S.
14.1.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in the U.S.
14.1.5. Market size of CALD by Segmentation in the U.S.
14.1.6. Therapy-based Market size of CALD in the U.S.
14.2. EU-5: Market Analysis
14.3. Germany
14.3.1. Market Size of ALD in the Germany
14.3.2. Market size of ALD by Segmentation in Germany
14.3.3. Therapy-based Market Size of ALD in Germany
14.3.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Germany
14.3.5. Market size of CALD by Segmentation in Germany
14.3.6. Therapy-based Market size of CALD in Germany
14.4. France
14.4.1. Market Size of ALD in France
14.4.2. Market size of ALD by Segmentation in France
14.4.3. Therapy-based Market Size of ALD in France
14.4.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in France
14.4.5. Market size of CALD by Segmentation in France
14.4.6. Therapy-based Market size of CALD in France
14.5. Italy
14.5.1. Market Size of ALD in Italy
14.5.2. Market size of ALD by Segmentation in Italy
14.5.3. Therapy-based Market Size of ALD in Italy
14.5.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Italy
14.5.5. Market size of CALD by Segmentation in Italy
14.5.6. Therapy-based Market size of CALD in Italy
14.6. Spain
14.6.1. Market Size of ALD in Spain
14.6.2. Market size of ALD by Segmentation in Spain
14.6.3. Therapy-based Market Size of ALD in Spain
14.6.4. Market size of Cerebral Adrenoleukodystrophy [CALD] in Spain
14.6.5. Market size of CALD by Segmentation in Spain
14.6.6. Therapy-based Market size of CALD in Spain

15. Japan: Market Analysis
15.1. Market Size of ALD in Japan
15.2. Market size of ALD by Segmentation in Japan
15.3. Market size of Cerebral Adrenoleukodystrophy [CALD] in Japan

16. Market Drivers

17. Market Barriers

18. Appendix

19. Report Methodology
19.1. Sources used

20. Capabilities

21. Disclaimer

22. About the Publisher

List of Tables
Table 1: X-ALD Phenotypes in Males
Table 2: Phenotype in Female X-ALD carriers
Table 3: the X-ALD Phenotypes
Table 4: MRI Severity Scale
Table 5: MRI Severity Rating (Loes Score)
Table 6: Neurological Function Score (NFS Score)
Table 7: X-linked Adrenoleukodystrophy- Disability Rating Scale (ALD-DRS)
Table 8: Prevalent Population of Adrenoleukodystophy in the 7MM (2016-2027)
Table 9: Prevalent Population of Adrenoleukodystrophy in United States (2016-2027)
Table 10: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2027)
Table 11: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2027)
Table 12: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2027)
Table 13: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2027)
Table 14: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2027)
Table 15: Prevalent Population of Adrenoleukodystrophy in France (2016-2027)
Table 16: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2027)
Table 17: Diagnosed Prevalence of CALD by Segmentation in France (2016-2027)
Table 18: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2027)
Table 19: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2027)
Table 20: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2027)
Table 21: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2027)
Table 22: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2027)
Table 23: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2027)
Table 24: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2027)
Table 25: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2027)
Table 26: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2027)
Table 27: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2027)
Table 28: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2027)
Table 29: Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2027)
Table 30: X-linked Adrenoleukodystrophy Phenotypes Treatment
Table 31: Recommendations for Addison Disease
Table 32: Hormonal therapies for Addison Disease
Table 33: Adrenoleukodystrophy treatment
Table 34: Adrenoleukodystrophy treatment
Table 35: Phase II/III Drug analysis
Table 36: Phase I/II/III Drug analysis
Table 37: Lenti D, Clinical Trial Description, 2018
Table 38: MIN-102, Clinical Trial Description, 2018
Table 39: MD1003, Clinical Trial Description, 2018
Table 40: NV1205, Clinical Trial Description, 2018
Table 41: Forecasting parameters and assumptions for Market Forecast in 7MM (2016-2027)
Table 42: 7MM Major Market Size of ALD in USD Million (2016-2027)
Table 43: Market Size of ALD by Segmentation in 7MM in USD Million (2016-2027)
Table 44: Therapy Based US Market Size of CALD in USD Million (2016-2027)
Table 45: Market Size of CALD in 7MM in USD Million (2016-2027)
Table 46: Market Size of CALD by Segmentation in 7MM in USD Million (2016-2027)
Table 47: 7MM Therapy Based Market Size of CALD in USD Million (2016-2027)
Table 48: U.S. Market Size of ALD in USD Million (2016-2027)
Table 49: U.S. Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 50: Therapy Based US Market Size of ALD in USD Million (2016-2027)
Table 51: U.S. Market Size of CALD in USD Million (2016-2027)
Table 52: U.S. Market Size of CALD by Segmentation in USD Million (2016-2027)
Table 53: Therapy Based US Market Size of CALD in USD Million (2016-2027)
Table 54: Germany Market Size of ALD in USD Million (2016-2027)
Table 55: Germany Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 56: Therapy Based Germany Market Size of ALD in USD Million (2016-2027)
Table 57: Germany Market Size of CALD in USD Million (2016-2027)
Table 58: Germany Market Size of CALD by Segmentation in USD Million (2016-2027)
Table 59: Therapy Based Germany Market Size of CALD in USD Million (2016-2027)
Table 60: France Market Size of ALD in USD Million (2016-2027)
Table 61: France Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 62: Therapy Based France Market Size of ALD in USD Million (2016-2027)
Table 63: France Market Size of CALD in USD Million (2016-2027)
Table 64: France Market Size of CALD by Segmentation in USD Million (2016-2027)
Table 65: Therapy Based France Market Size of CALD in USD Million (2016-2027)
Table 66: Italy Market Size of ALD in USD Million (2016-2027)
Table 67: Italy Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 68: Therapy Based Italy Market Size of ALD in USD Million (2016-2027)
Table 69: Italy Market Size of CALD in USD Million (2016-2027)
Table 70: Italy Market Size of CALD by Segmentation in USD Million (2016-2027)
Table 71: Therapy Based Italy Market Size of CALD in USD Million (2016-2027)
Table 72: Spain Market Size of ALD in USD Million (2016-2027)
Table 73: Spain Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 74: Therapy Based Italy Market Size of ALD in USD Million (2016-2027)
Table 75: Spain Market Size of CALD in USD Million (2016-2027)
Table 76: Spain Market Size of CALD by Segmentation in USD Million (2016-2027)
Table 77: Therapy Based Italy Market Size of CALD in USD Million (2016-2027)
Table 78: Japan Market Size of ALD in USD Million (2016-2027)
Table 79: Spain Market Size of ALD by Segmentation in USD Million (2016-2027)
Table 80: Japan Market Size of CALD in USD Million (2016-2027)

List of Figures
Figure 1: Evolution of Phenotypes in X-ALD
Figure 2: Clinical Spectrum of X-ALD
Figure 3: Inheritance spectrum of X-ALD
Figure 4: Pathogenesis of VLCFA
Figure 5: Principles of ALD 3-tier screening
Figure 6: Diagnostic algorithm for diagnosis of adrenoleukodystrophy
Figure 7: Prevalent Population of X-Adrenoleukodystophy in the 7MM (2016-2027)
Figure 8: Prevalent Population of Adrenoleukodystrophy in United States (2016-2027)
Figure 9: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2027)
Figure 10: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2027)
Figure 11: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2027)
Figure 12: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2027)
Figure 13: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2027)
Figure 14: Prevalent Population of Adrenoleukodystrophy in France (2016-2027)
Figure 15: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2027)
Figure 16: Diagnosed Prevalence of CALD by Segmentation in France (2016-2027)
Figure 17: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2027)
Figure 18: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2027)
Figure 19: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2027)
Figure 20: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2027)
Figure 21: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2027)
Figure 22: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2027)
Figure 23: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2027)
Figure 24: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2027)
Figure 25: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2027)
Figure 26: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2027)
Figure 27: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2027)
Figure 28 Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2027)
Figure 29: Treatment General Practices
Figure 30: Out-patient management of X-ALD
Figure 31: Follow-up for pre-symptomatic ALD
Figure 32: Unmet Needs of Adrenoleukodystrophy
Figure 33: 7 Major Market Size of ALD in USD Million (2016-2027)
Figure 34: Market Size of ALD by Segmentation in 7MM in USD Million (2016-2027)
Figure 35: 7MM Therapy Based Market Size of ALD in USD Million (2016-2027)
Figure 36: Market Size of CALD in 7MM in USD Million (2016-2027)
Figure 37: Market Size of CALD by Segmentation in 7MM in USD Million (2016-2027)
Figure 38: 7MM Therapy Based Market Size of CALD in USD Million (2016-2027)
Figure 39: U.S. Market Size of ALD in USD Million (2016-2027)
Figure 40: US Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 41: Therapy Based US Market Size of ALD in USD Million (2016-2027)
Figure 42: U.S. Market Size of CALD in USD Million (2016-2027)
Figure 43: U.S. Market Size of CALD by Segmentation in USD Million (2016-2027)
Figure 44: Therapy Based US Market Size of CALD in USD Million (2016-2027)
Figure 45: Germany Market Size of ALD in USD Million (2016-2027)
Figure 46: Germany Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 47: Therapy Based Germany Market Size of ALD in USD Million (2016-2027)
Figure 48: Germany Market Size of CALD in USD Million (2016-2027)
Figure 49: Germany Market Size of CALD by Segmentation in USD Million (2016-2027)
Figure 50: Therapy Based Germany Market Size of CALD in USD Million (2016-2027)
Figure 51: France Market Size of ALD in USD Million (2016-2027)
Figure 52: France Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 53: Therapy Based France Market Size of ALD in USD Million (2016-2027)
Figure 54: France Market Size of CALD in USD Million (2016-2027)
Figure 55: France Market Size of CALD by Segmentation in USD Million (2016-2027)
Figure 56: Therapy Based France Market Size of CALD in USD Million (2016-2027)
Figure 57: Italy Market Size of ALD in USD Million (2016-2027)
Figure 58: Italy Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 59: Therapy Based Italy Market Size of ALD in USD Million (2016-2027)
Figure 60: Italy Market Size of CALD in USD Million (2016-2027)
Figure 61: Italy Market Size of CALD by Segmentation in USD Million (2016-2027)
Figure 62: Therapy Based Italy Market Size of CALD in USD Million (2016-2027)
Figure 63: Spain Market Size of ALD in USD Million (2016-2027)
Figure 64: Spain Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 65: Therapy Based Spain Market Size of ALD in USD Million (2016-2027)
Figure 66: Spain Market Size of CALD in USD Million (2016-2027)
Figure 67: Spain Market Size of CALD by Segmentation in USD Million (2016-2027)
Figure 68: Therapy Based Spain Market Size of CALD in USD Million (2016-2027)
Figure 69: Japan Market Size of ALD in USD Million (2016-2027)
Figure 70: Japan Market Size of ALD by Segmentation in USD Million (2016-2027)
Figure 71: Japan Market Size of CALD in USD Million (2016-2027)
Figure 72: Market Drivers
Figure 73: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll